A Mixed Set Of Results From 5-Alpha-Reductase Inhibitors And Reduced Prostate Cancer Risk

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man’s risk of being diagnosed with prostate cancer from around 5-9% to around 4-6% during up to 7 years of treatment, according to a new Cochrane Review. However, those who are diagnosed with prostate cancer may be at a slightly increased risk of having a more dangerous (high grade) tumour.

More: continued here

Filed under: Endocrinology on April 17th, 2008